argenx SE/€ARGX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About argenx SE
Argenx SE is a biotechnology company primarily engaged in the development of antibody-based therapies for the treatment of severe autoimmune diseases and cancer. The company leverages its proprietary SIMPLE Antibody™ platform to create differentiated immunology solutions. One of its flagship products is efgartigimod, designed to target the neonatal Fc receptor (FcRn) to modulate antibody levels, which has gained significant attention in therapeutic areas such as neuromuscular disorders. Founded in 2008, Argenx is headquartered in Ghent, Belgium, and has expanded its operations globally. The company's strategic positioning lies in its ability to combine deep insights into disease biology with cutting-edge technology to create novel treatments. Sources:
- Argenx Official Website: www.argenx.com
- "Argenx - Company Profile and News," Bloomberg, www.bloomberg.com
- Ticker
- €ARGX
- Sector
- Health
- Primary listing
- BSE
- Employees
- 1,863
- Headquarters
- Amsterdam, Netherlands
- Website
- argenx.com
argenx SE Metrics
BasicAdvanced
€49B
30.23
€25.78
-0.04
-
Price and volume
Market cap
€49B
Beta
-0.04
52-week high
€924.40
52-week low
€564.60
Average daily volume
97K
Financial strength
Total debt to equity
0.006
Interest coverage (TTM)
595.15%
Profitability
EBITDA (TTM)
1,697.025
Gross margin (TTM)
59.84%
Net profit margin (TTM)
31.73%
Operating margin (TTM)
31.94%
Effective tax rate (TTM)
1.14%
Revenue per employee (TTM)
€2,838,690
Management effectiveness
Valuation
Price to earnings (TTM)
30.229
Price to revenue (TTM)
9.18
Price to book
5.81
Price to tangible book (TTM)
6
Growth
Revenue change (TTM)
60.60%
Earnings per share change (TTM)
24.08%
3-year revenue growth (CAGR)
79.16%
10-year revenue growth (CAGR)
79.29%
3-year earnings per share growth (CAGR)
90.60%
What the Analysts think about argenx SE
Analyst ratings (Buy, Hold, Sell) for argenx SE stock.
Analyst projections of the future price of argenx SE stock.
Bulls say / Bears say
VYVGART delivered $1.5 billion in second-quarter sales, up 60% year on year and 17% from the prior quarter, while operating profit reached $494 million. That strong growth shows the commercial franchise is still expanding. (argenx)
The FDA expanded VYVGART’s US gMG label to cover all serotypes, including seronegative patients. This removes a previous patient-group limitation and broadens the pool of people eligible for treatment. (U.S. Securities and Exchange Commission)
Efgartigimod met the primary endpoint in the Phase 3 ALKIVIA myositis study, supporting a potential move into another autoimmune indication. The result could extend the reach of an already commercialised medicine if regulators approve it. (argenx)
The Phase 3 UNITY study in Sjögren’s disease was stopped for futility after an interim review found it was unlikely to meet its primary endpoint. This removes one potential use for efgartigimod and highlights the risk that pipeline expansion will not succeed in every disease. (FinancialContent)
First-half 2026 product sales came from VYVGART, leaving argenx commercially reliant on one franchise. The company also identifies competition as a business risk, so rival treatments or pricing pressure could have an outsized effect on sales. (U.S. Securities and Exchange Commission)
The $2.2 billion Forte Biosciences acquisition was described as a substantial premium for FB-102, which was still an investigational asset. The deal adds clinical and integration risk before the acquired programme has established late-stage or commercial value. (Seeking Alpha)
Data summarised monthly by Lightyear AI. Last updated on 8 Oct 2026.
argenx SE Financial Performance
Revenues and expenses
argenx SE Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing argenx SE
AllEURUSD
Fund name | Fund size | €ARGX weighting |
|---|---|---|
iShares MSCI Europe Health Care Sector£ESIH | €890M | 2.92% |
iShares MSCI Europe Health Care Sector€ESIH | €890M | 2.92% |
iShares STOXX Europe 600 Health Care€EXV4 | €709M | 2.79% |
iShares Healthcare Innovation$HEAL | $1.3B | 1.19% |
iShares Healthcare Innovation€2B78 | $1.2B | 1.19% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.